:: Library Catalog

Cover Image

Saved in:

Bibliographic Details
Main Author:	Nehad Jaser Ahmed
Format:	Recurso digital
Language:
Published:	Zenodo 2026
Online Access:	https://doi.org/10.5281/zenodo.18952959
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Descriptive Analysis of Ranolazine Adverse Events Reported in the FDA Adverse Event Reporting System (FAERS)
by: Nehad Jaser Ahmed
Published: (2026)

DOFETILIDE Descriptive Analysis of Adverse Events Reported in the FDA Adverse Event Reporting System (FAERS)
by: Nehad Jaser Ahmed
Published: (2026)

Labetalol: A Descriptive Analysis of Adverse Events Reported in the FDA Adverse Event Reporting System (FAERS)
by: Nehad Jaser Ahmed
Published: (2026)

Prazosin Adverse Events: A Descriptive Analysis of the FDA Adverse Event Reporting System (FAERS)
by: Nehad Jaser Ahmed
Published: (2026)

HYDROCHLOROTHIAZIDE ADVERSE EVENTS A Descriptive Analysis of Adverse Events Reported in the FDA Adverse Event Reporting System (FAERS)
by: Nehad Jaser Ahmed
Published: (2026)

Descriptive Analysis of Amiloride Adverse Events Reported in the FDA Adverse Event Reporting System (FAERS): A Retrospective Pharmacovigilance Study
by: Nehad Jaser Ahmed
Published: (2026)

Descriptive Analysis of Alteplase Adverse Events Reported in the FDA Adverse Event Reporting System (FAERS): A Retrospective Pharmacovigilance Study
by: Nehad Jaser Ahmed
Published: (2026)

Adverse Event Profile of Spiramycin: A Comprehensive Pharmacovigilance Analysis of the FDA Adverse Event Reporting System (FAERS) Database
by: Nehad Jaser Ahmed
Published: (2026)

Indications and Adverse Events of Toradol: Based on FDA Adverse Event Reporting System (FAERS)
by: Jiaqi Guo, et al.
Published: (2026)

Adverse Events Associated With Dabrafenib, Trametinib, and Their Combination Therapy: A Disproportionality Analysis of the FDA Adverse Event Reporting System ( FAERS ) Database
by: Zhenpo Zhang, et al.
Published: (2025)

Evaluating the Evolving Real‐World Adverse Events of GLP ‐ 1RAs Using FDA Adverse Event Reporting System ( FAERS )
by: David Stone, et al.
Published: (2026)

Pharmacovigilance Analysis of Drug-Induced Rhabdomyolysis Based on the FDA Adverse Event Reporting System (FAERS)
by: Liang, Enpu
Published: (2025)

Low‐Dose Oral Minoxidil and Associated Adverse Events: Analyses of the FDA Adverse Event Reporting System ( FAERS ) With a Focus on Pericardial Effusions
by: Aditya K. Gupta, et al.
Published: (2024)

A Real‐World Pharmacovigilance Study of Fruquintinib Based on the FDA Adverse Event Reporting System ( FAERS ) Database
by: Yajing Xu, et al.
Published: (2025)

ADHD medications and drug withdrawal: A pharmacovigilance study using the FDA Adverse Event Reporting System (FAERS) database
by: Takumi Ebina, et al.
Published: (2026)

Cardiovascular and Metabolic Adverse Events of Endocrine Therapies in Women with Breast Cancer: A Disproportionality Analysis of Reports in the FDA Adverse Event Reporting System
by: Shaimaa Elshafie, et al.
Published: (2024)

Safety analysis of gepants for migraine treatment: A pharmacovigilance study using the FDA Adverse Event Reporting System ( FAERS ) database
by: Hui Chen, et al.
Published: (2026)

Aioli: Standardising Drugs in the FDA Adverse Event Reporting System ( FAERS ) to RxNorm and Anatomical Therapeutic Chemical ( ATC ) Codes
by: Rowan E. Parry, et al.
Published: (2025)

Comprehensive safety assessment of ribociclib: A real‐world analysis using the FDA Adverse Event Reporting System (FAERS) database
by: Lan Luo, et al.
Published: (2025)

Vismodegib and Sonidegib Are Associated With an Elevated Reporting Odds of Squamous Cell Carcinoma; a Comparative Pharmacovigilance Study of the FDA Adverse Events Reporting System ( FAERS )
by: Patrick Jedlowski, et al.
Published: (2025)

FDA Adverse Event Reporting System Essentials: A Reflection on Study Conception
by: Emanuel Raschi, et al.
Published: (2025)

A Real‐World Study on Adverse Reactions of Belimumab Based on the FDA Adverse Event Reporting System Database
by: Le Hai, et al.
Published: (2024)

The Cardiovascular Safety of Antiparkinsonian Drugs—Analysis of Signals in the FDA Adverse Event Report System Database
by: Xin Mu, et al.
Published: (2026)

Drug‐Related Hypertension: A Disproportionality Analysis Leveraging the FDA Adverse Event Reporting System
by: Hao Zhu, et al.
Published: (2025)

A Real‐World Pharmacovigilance Study of FDA Adverse Event Reporting System Events for Obeticholic Acid
by: Le Hai, et al.
Published: (2025)

Bridging FDA Adverse Event Reporting System ( FAERS ) and Clinical Practice: Comprehensive Characterization of Immune Checkpoint Inhibitors Toxicities in Geriatric Lung Cancer Patients
by: Yumeng Tian, et al.
Published: (2026)

Analysis of Predictors of Adverse Events and Mortality Risk Associated With IL‐6 Inhibitors: A Pharmacovigilance Study Using the FDA Adverse Event Reporting System Database
by: Meilin Fang, et al.
Published: (2025)

Gastrointestinal Perforations Associated With JAK Inhibitors: A Disproportionality Analysis of the FDA Adverse Event Reporting System
by: Adam Goldman, et al.
Published: (2024)

100 Short Answer Questions about Sexually Transmitted Infections, prepared by Dr. Nehad Jaser Ahmed using Claude
by: Nehad Jaser Ahmed
Published: (2026)

100 Fill-in-the-Blank Questions about Antimicrobial Prophylaxis in Surgery, prepared by Dr. Nehad Jaser Ahmed using Claude
by: Nehad Jaser Ahmed
Published: (2026)

100 Short Answer Questions about Infections in Immunocompromised Patients, prepared by Dr. Nehad Jaser Ahmed using Claude
by: Nehad Jaser Ahmed
Published: (2026)

100 Short Answer Questions about Invasive Fungal Infections, prepared by Dr. Nehad Jaser Ahmed using Claude
by: Nehad Jaser Ahmed
Published: (2026)

100 Fill-in-the-Blank Questions about Sepsis and Septic Shock, prepared by Dr. Nehad Jaser Ahmed using Claude
by: Nehad Jaser Ahmed
Published: (2026)

100 Matching Questions about Skin and Soft Tissue Infections prepared by Dr. Nehad Jaser Ahmed using Claude
by: Nehad Jaser Ahmed
Published: (2026)

100 Fill-in-the-Blank Questions about Tuberculosis, prepared by Dr. Nehad Jaser Ahmed using Claude
by: Nehad Jaser Ahmed
Published: (2026)

100 Short Answer Questions about INFLUENZA, prepared by Dr. Nehad Jaser Ahmed using Claude
by: Nehad Jaser Ahmed
Published: (2026)

Comparative Post‐Marketing Surveillance of Memantine and Cholinesterase Inhibitors: Cardiovascular Adverse Events With a Focus on Sex Differences Using the FDA Adverse Event Reporting System Database
by: Zinnet Şevval Aksoyalp, et al.
Published: (2024)

A Feasibility Assessment of the FDA Adverse Event Reporting System for the Detection of Cannabis‐Related Safety Signals
by: Priscilla O. M. V. Lopes, et al.
Published: (2026)

Post‐Marketing Safety of Bimekizumab in Psoriasis Patients: Pharmacovigilance Data From FDA Adverse Event Reporting System
by: Tung S. Tran, et al.
Published: (2025)

Adverse Event Assessment of Upadacitinib: A Pharmacovigilance Study Based on the FAERS Database
by: Jiayu Yuan, et al.
Published: (2024)